Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Synmosa Biopharma Corporation (4114.TWO)
Taipei, TW
Synmosa Biopharma Corporation, established in Taipei, Taiwan, in 1980, operates as a dedicated specialty pharmaceutical enterprise. The company manages the entire lifecycle of pharmaceutical and healthcare products, from research and development to manufacturing, marketing, and distribution, primarily serving the Taiwanese market under its proprietary Synmosa brand. Its diverse product portfolio addresses key therapeutic categories, including cardiovascular health, respiratory conditions, urology, sex hormone treatments, and oncology. These offerings are available in various formats such as effervescent tablets, granules, nasal sprays, metered-dose inhalers, hormonal preparations, and other specialized forms. Beyond its proprietary products, Synmosa also extends its expertise through contract manufacturing services. The company maintains a significant international presence, exporting its goods to numerous countries including South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.33% | -2.11% | -2.11% | -5.93% | -6.22% | -6.94% | +4.54% | +7.33% | +134.08% | +215.05% | +1,446.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-10 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+11.5% ★ Q1'26: +12.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+3.1% Q1'26: -20.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+1.1% Q1'26: +13.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+12.6% Q1'26: +11.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.2% Q1'26: +5.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-12.2% ★ Q1'26: +16.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.23× ★ Q1'26: 2.36× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.78B
est.
|
2.08B
est.
|
1.84B
est.
|
2.35B
est.
|
2.68B
est: 2.67B (+0.4%)
|
3.04B
est: 2.96B (+2.5%)
|
3.23B
est: 3.19B (+1.5%)
|
4.39B
est: 4.37B (+0.3%)
|
5.14B
est: 5.21B (-1.3%)
|
5.55B
est: 5.46B (+1.6%)
|
6.19B
est: 6.19B (+0.0%)
|
6.82B
6.82B – 6.82B
+10.1% YoY
|
| EBITDA |
382.81M
est.
|
448.07M
est.
|
395.55M
est.
|
505.58M
est.
|
183.79M
est: 574.49M (-68.0%)
|
852.62M
est: 638.23M (+33.6%)
|
507.92M
est: 686.03M (-26.0%)
|
1.10B
est: 941.62M (+17.3%)
|
1.01B
est: 1.12B (-10.0%)
|
1.06B
est: 1.01B (+5.1%)
|
778.48M
est: 1.14B (-31.8%)
|
1.26B
1.26B – 1.26B
+10.1% YoY
|
| EBIT |
242.85M
est.
|
284.26M
est.
|
250.94M
est.
|
320.75M
est.
|
-90.24M
est: 364.46M (-124.8%)
|
550.47M
est: 404.89M (+36.0%)
|
205.86M
est: 435.22M (-52.7%)
|
784.59M
est: 597.37M (+31.3%)
|
668.82M
est: 711.16M (-6.0%)
|
717.17M
est: 871.44M (-17.7%)
|
778.48M
est: 987.07M (-21.1%)
|
1.09B
1.09B – 1.09B
+10.1% YoY
|
| Net Income |
108.74M
est.
|
175.23M
est.
|
367.43M
est.
|
477.45M
est.
|
47.09M
est: 102.59M (-54.1%)
|
638.11M
est: 476.41M (+33.9%)
|
303.86M
est: 130.63M (+132.6%)
|
799.09M
est: 769.95M (+3.8%)
|
594.83M
est: 547.28M (+8.7%)
|
684.68M
est: 720.81M (-5.0%)
|
618.43M
est: 618.42M (+0.0%)
|
674.31M
674.31M – 674.31M
+9.0% YoY
|
| SGA |
464.66M
est.
|
543.87M
est.
|
480.13M
est.
|
613.69M
est.
|
671.13M
est: 697.32M (-3.8%)
|
817.24M
est: 774.69M (+5.5%)
|
883.58M
est: 832.71M (+6.1%)
|
1.15B
est: 1.14B (+0.5%)
|
1.29B
est: 1.36B (-5.4%)
|
1.40B
est: 1.13B (+23.6%)
|
—
est: 1.28B (-100.0%)
|
1.41B
1.41B – 1.41B
+10.1% YoY
|
| EPS |
0.26
est.
|
0.41
est.
|
0.87
est.
|
1.13
est.
|
0.13
est: 0.24 (-46.3%)
|
1.99
est: 1.12 (+77.2%)
|
0.84
est: 0.31 (+172.7%)
|
2.25
est: 1.82 (+23.9%)
|
1.45
est: 1.29 (+12.4%)
|
1.47
est: 1.93 (-24.0%)
|
1.66
est: 1.66 (+0.0%)
|
1.81
1.81 – 1.81
+9.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.03% | 38.6K | 0.42% |
| 2 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 42.8K | 0.56% |
| 3 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.42M | 0.06% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.01% | 192.8K | 0.46% |
| 5 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 55.2K | 0.44% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.01% | 600.5K | 0.39% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 109.2K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 48.4K | 0.48% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 330.8K | 0.29% |
| 10 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 5.39M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhihui Lin | Chairman, GM, Managerial Officer & President | 5M | male |
| Hong-Qin Bai | Senior Vice President & Finance Officer | 4M | male |
| Sheng-Ren Yang | Senior Vice President | 3M | male |
| Jia-Xin Zhang | Senior Vice President | 3M | female |
| Liyu Huang | Chief Financial Officer | — | — |
| Ching-Hua Tsao | Accounting Officer | — | — |
| Zen Young | Vice President of Sales - HP, Marketing & Medical | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4114.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
